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Summary
The objective of this study was to determine if the current dosage regimen for chloramphenicol (CAP)
administered to children with severe malaria (SM) for presumptive treatment of concomitant bacterial
meningitis achieves steady state plasma CAP concentrations within the reported therapeutic range
of 10–25mg/l. Fifteen children (11 male, 4 female) with a median age of 45 months (range:
10–108months) and having SM, were administered multiple intravenous doses (25mg/kg, 6 hourly for
72 h) of chloramphenicol sodium succinate (CAPS) for presumptive treatment of concomitant bacterial
meningitis. Blood samples were collected over 72 h, and plasma CAPS, CAP and CSF CAP concen-
trations determined by high performance liquid chromatography. Average steady state CAP
concentrations were approximately 17mg/l, while mean fraction unbound (0.49) and CSF/plasma
concentration ratio (0.65) were comparable to previously reported values in Caucasian children.
Clearance was variable (mean^ 4.3 l/h), and trough plasma concentrations during the first dosing
interval were approximately 6mg/l. Simulations indicated that an initial of loading dose of 40mg/kg
CAPS, followed by a maintenance dose of 25mg/kg every 6 h would result in trough CAP
concentrations of approximately 10mg/l and peak concentrations _25mg/l throughout the treatment
period. The current dosage regimen for CAP needs to include a loading dose of 40mg/kg CAPS to
rapidly achieve plasma CAP concentrations within the reported therapeutic range.
Introduction
Severe falciparum malaria is a major cause of
childhood mortality in sub-Saharan Africa,1,2
Bacterial infections often complicate severe malaria
in children. In Kenyan children admitted to hospital
with malaria, 7.8 per cent have been shown to have a
bacteraemia and this is associated with a three fold
increase in mortality.3,4 Furthermore, it is difficult to
clinically distinguish between cerebral malaria and
bacterial meningitis, and antimicrobials are often
administered until the results of the lumbar puncture
are known.5 Thus, in resource poor countries
(RPCs), presumptive treatment with chlorampheni-
col and benzyl penicillin is often started until the
cultures of blood and cerebrospinal fluid (CSF) are
available.
In severely ill children, chloramphenicol is
administered intravenously as the inactive prodrug,
chloramphenicol sodium succinate, which has no
antibacterial activity, and must be hydrolysed in
the liver to generate the active chloramphenicol.
The bioavailability of chloramphenicol from the
intravenously administered prodrug is determined
both by the extent of hydrolysis and renal excretion
of the prodrug.6 Studies in children6,7 and adults8
have shown that hydrolysis of chloramphenicol
succinate to chloramphenicol in vivo is often incom-
plete and variable. In infants and children, the
clearance of chloramphenicol and chloramphenicol
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succinate has been reported to exhibit wide inter-
individual variability. Furthermore, there is evidence
suggesting that hepatocellular dysfunction associated
with infections could impair metabolism of chlor-
amphenicol.9 The therapeutic range for chloram-
phenicol is thought to be between 10–20mg/l,10,11
and dose-related toxicity is associated with peak
concentrations 425mg/l.12
Chloramphinicol is included in the WHO list of
essential drugs, and is still widely used in many RPCs
because it is cheap and readily available. Its phar-
macokinetics have been described in African infants
53 months13 but detailed pharmacokinetics in
older African children have only been reported in
two studies in malnourished children.14,15 Thus, the
current dosage regimens for chloramphenicol in
many RPCs have not been evaluated in many of
the populations in which they are used. In particular,
malaria infection in children may be associated with
a degree of hepatic dysfunction2 that may affect
the pharmacokinetics of chloramphenicol. Children
with malaria also receive other concurrent drugs
such as phenytoin, phenobarbitone and paracetamol
which have been reported to interact with chloram-
phenicol.16–19
We have studied the pharmacokinetics of intrave-
nous chloramphenicol succinate in children with SM
to assess whether the current dosage regimen rapidly
achieves plasma chloramphenicol concentrations
within the range of 10–25mg/l.
Methods
Setting
The study was conducted at the Kenya Medical
Research Institute (KEMRI) Unit, Kilifi District
Hospital (KDH), on the Kenyan coast. The study
formed part of a larger study on the effect of
concomitant administration of chloramphenicol on
pharmacokinetics of phenytoin in children with
severe malaria and bacterial infections,20 and was
approved by the KEMRI Ethics Committee.
Patients
Children admitted to the KEMRI paediatric ward at
the KDH were recruited into the study if: (i) they
were aged 9 months to 13 years; (ii) they had features
of severe falciparum malaria1 and; (iii) if the parents/
guardian gave a written informed consent. Details
of the clinical management have been described
elsewhere.20
Chloramphenicol administration and blood
and CSF sampling
Chloramphenicol sodium succinate (Lincoln
Pharmaceuticals Ltd., Nirav Complex, Ahmedabad,
India) was administered intravenously (25mg/kg,
6 hourly for 72 h) as a bolus over 1min. Blood
samples (0.4ml), from which plasma was obtained
for measuring chloramphenicol and chloramphenicol
succinate concentrations,21 were collected at various
times over 72 h. In those patients who had a lumbar
puncture performed for clinical purposes, an aliquot
(100ml) of CSF was obtained and stored at 20C
until assayed for chloramphenicol.21
Pharmacokinetic analysis
Plasma chloramphenicol and chloramphenicol succi-
nate concentration-time data during the first 6 h
dosing interval were simultaneously fitted to the
model shown in Fig. 1, using the pharmacokinetic
programme TopFit.22 Simulations of plasma chlor-
amphenicol concentrations were also performed using
TopFit. Estimated pharmacokinetic parameters were
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Fig. 1. Schematic representation of in vivo disposition of chloramphenicol sodium succinate.
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summarised as mean [95 per cent confidence interval,
(CI)] or median (range). The 95 per cent CI was
estimated using the statistical program CIA.23
Results
Fifteen children (4 females and 11 males) were
recruited into the study (Table 1).
Estimated mean steady state total chlorampheni-
col concentrations (Css) were within the reported
therapeutic range of 10–25mg/l (Table 2), although
trough concentrations were 510mg/l after the first
dose. Simulations indicated that a loading dose of
40mg/kg, followed by a maintenance dose of 25mg/
kg every 6 h would rapidly achieve and maintain
plasma chloramphenicol concentrations within the
therapeutic range throughout the treatment period
(Fig. 2). Lumbar punctures were performed within a
median time of 5 h (range: 2–6 h) after administration
of the last dose of chloramphenicol succinate.
Concentrations of chloramphenicol in CSF ranged
from 4.4 to 13.2mg/l (Fig. 3), above the MIC for
all the isolates Streptococcus pneumoniae, the main
cause of bacterial meningitis in this hospital.24
Discussion
Chloramphenicol is still routinely used in resource-
poor countries (RPCs) for treatment of bacterial
infections including bacterial meningitis despite con-
cerns about its adverse effects, since it is cheap,
widely available and a broad-spectrum antibiotic.
The regimen we studied is recommended by the
WHO and the British National Formulary, and is
widely used in health facilities in rural Africa. It does
not include administration of a loading dose. Based
on the pharamcokinetic data generated from this
study, we recommend that an initial loading dose of
40mg/kg be administered to ensure that chloram-
phenicol trough and peak concentrations of approxi-
mately 10 and 20mg/l, respectively, are achieved
during the first 6 h when such children are most
critically ill. Most children in this study received
paracetamol for treatment of fever. In addition, all
children received phenytoin. Although these drugs
have been reported to interact with chlorampheni-
col,16,18,19 we did not find any significant effect of
concomitant administration of these drugs on the
clearance of chloramphenicol.
The mean CSF: plasma chloramphenicol concen-
tration ratio estimated in this study (0.62) was similar
to previously reported values in Caucasian children
and infants.25 In addition, concentrations of chlor-
amphenicol in CSF from different children at
different times after drug administration were all
4mg/l (Fig. 3). The MIC for Streptococcus pneu-
monia, the main causative agent for bacterial
Table 1
Demographic and biochemical parameters. Values





Age (months) 49.4 (33.9, 64.9)
Weight (kg) 14.3 (12.2, 16.4)
Rectal temperature (C) 38.7 (37.9, 39.5)
WAZ (weight for age) score 20.2 (2.64, 1.4)
Laboratory measurements
Haemoglobin (g/dl) 8.20 (6.95, 9.45)




Total plasma proteins (g/l) 62.1 (57.3, 66.7)
Plasma albumin (g/l) 32.3 (29.8, 34.8)
Sodium (mmol/l) 132.7 (129.4, 136.1)
Potassium (mmol/l) 4.31 (3.85, 4.76)
Creatinine (mmol/l) 74.4 (46.6, 100.2)
pH 7.32 (7.27, 7.37)
Blood glucose (mmol/l) 5.84 (3.94, 7.73)
Base excess 9.15 (10.9, 7.4)
Table 2
Pharmacokinetic parameters of chloramphenicol (CAP) and chloramphenicol succinate (CAPS) in children
with severe malaria
Parameter n Mean (sd) or median (range) 95 per cent confidence interval
AUC (mg/mlh) 13 99.6 (22) 86.6–113
CSS total (mg/ml) 13 16.7 (3.7) 14.4–18.9
CSS free (mg/ml) 9 8.7 (2.3) 6.9–10.5
Cmax total (mg/ml)
 13 14.1 (11.8–20) 12.8–16
Fraction unbound 9 0.49 (0.15) 0.38–0.60
CSF/plasma CAP ratio 13 0.65 (0.19) 0.54–0.76
CSF CAP conc (mg/ml) 13 7.6 (2.7) 5.9–9.2
Tmax (h)
 13 0.58 (0.25–1) 0.46–0.67
T½ (h), CAP 13 4.1 (0.7) 3.6–4.5
T½ (h), CAPS 13 0.16 (0.004) 0.14–0.19
CLTOTAL (l/h), CAP 13 4.3 (1.5) 3.34–5.16
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meningitis in children admitted to this hospital,24 was
estimated to be 2mg/l, while the National Committee
for Clinical Laboratory Standards criteria for sensi-
tive isolates is an MIC 4mg/l. Taken together, these
results support the use of chloramphenicol for
presumptive treatment of pneumoccocal meningitis
in our setting.
Conclusions and Recommendations
We have shown that the pharmacokinetics of
chloramphenicol in African children with severe
malaria are broadly similar to previous reports in
Caucasian children. Concomitantly administered
paracetamol and phenytoin do not appear to have
any effect on chloramphenicol pharmacokinetics.
To achieve and maintain therapeutic chloram-
phenicol concentrations rapidly and throughout
the treatment period, we recommend that a loading
dose of 40mg/kg chloramphenicol sodium succinate,
followed by a maintenance dose of 25mg/kg every
6 h should be administered.
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Fig. 2. Simulations of plasma chloramphenicol concentration-time profile that would be obtained after
administration of a 40mg/kg chloramphenicol sodium succinate loading dose followed by 25mg/kg maintenance
dose every 6 h for 72 h. For clarity, the 95 per cent confidence intervals are not shown in the figure.
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Fig. 3. Chloramphenicol concentrations in CSF at various times in different patients (n¼ 12). The dotted line is
the MIC for Streptococcus pneumoniae isolates from the hospital where the study was carried out (Kilifi District
Hospital, Kenya).
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